- Home
- EWCZ vs TSHA Comparison
EWCZ vs TSHA Comparison
Compare EWCZ & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- TSHA
- Stock Information
- Founded
- EWCZ 2004
- TSHA 2019
- Country
- EWCZ United States
- TSHA United States
- Employees
- EWCZ N/A
- TSHA N/A
- Industry
- EWCZ Package Goods/Cosmetics
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- EWCZ Consumer Discretionary
- TSHA Health Care
- Exchange
- EWCZ Nasdaq
- TSHA Nasdaq
- Market Cap
- EWCZ 166.5M
- TSHA 1.4B
- IPO Year
- EWCZ 2021
- TSHA 2020
- Fundamental
- Price
- EWCZ $3.82
- TSHA $4.19
- Analyst Decision
- EWCZ Hold
- TSHA Strong Buy
- Analyst Count
- EWCZ 6
- TSHA 9
- Target Price
- EWCZ $5.50
- TSHA $10.22
- AVG Volume (30 Days)
- EWCZ 378.4K
- TSHA 3.9M
- Earning Date
- EWCZ 11-12-2025
- TSHA 11-04-2025
- Dividend Yield
- EWCZ N/A
- TSHA N/A
- EPS Growth
- EWCZ 14.45
- TSHA N/A
- EPS
- EWCZ 0.26
- TSHA N/A
- Revenue
- EWCZ $211,264,000.00
- TSHA $6,310,000.00
- Revenue This Year
- EWCZ N/A
- TSHA N/A
- Revenue Next Year
- EWCZ $2.27
- TSHA N/A
- P/E Ratio
- EWCZ $14.64
- TSHA N/A
- Revenue Growth
- EWCZ N/A
- TSHA N/A
- 52 Week Low
- EWCZ $2.72
- TSHA $1.05
- 52 Week High
- EWCZ $8.91
- TSHA $5.51
- Technical
- Relative Strength Index (RSI)
- EWCZ 50.79
- TSHA 47.11
- Support Level
- EWCZ $3.57
- TSHA $3.69
- Resistance Level
- EWCZ $4.45
- TSHA $4.50
- Average True Range (ATR)
- EWCZ 0.20
- TSHA 0.37
- MACD
- EWCZ 0.03
- TSHA -0.09
- Stochastic Oscillator
- EWCZ 33.16
- TSHA 31.60
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.